Blog
RSS FeedPosted by Michael Wonder on 19 Jun 2023
SMC publishes a Collaborative Advice Document for tixagevimab-cilgavimab (Evusheld) for prevention of COVID-19
14 June 2023 - SMC has collaborated with NICE on Technology Appraisal, TA900: tixagevimab-cilgavimab for preventing COVID-19. ...
Posted by Michael Wonder on 13 Jun 2023
SMC accepts Rinvoq (upadacitinib) as a treatment option for adults with moderately to severely active Crohn’s disease in Scotland
12 June 2023 - The SMC decision is supported by data from three Phase 3 clinical trials demonstrating upadacitinib achieved ...
Posted by Michael Wonder on 12 Jun 2023
SMC - June 2023 decisions
12 June 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 31 May 2023
Streamlining SMC processes for medicines that clearly offer good value to NHSScotland
30 May 2023 - Following a positive stakeholder evaluation, a change to SMC process for medicines introduced on an interim ...
Posted by Michael Wonder on 09 May 2023
SMC - May 2023 decisions
9 May 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 13 Mar 2023
SMC - March 2023 decisions
13 March 2023 - The SMC which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 14 Feb 2023
Scotland becomes first part of UK to approve new cervical cancer drug
13 February 2023 - The SMC has approved the use of the drug pembrolizumab – which is also known as ...
Posted by Michael Wonder on 13 Feb 2023
SMC - February 2023 decisions
13 February 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 08 Feb 2023
Speeding up access to new medicines in Scotland: abbreviated process
8 February 2023 - A process brought in to streamline decision-making around access to new medicines in NHSScotland during the ...
Posted by Michael Wonder on 19 Jan 2023
Scottish Medicines Consortium recommends Merck’s Tepmetko
18 January 2023 - Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients ...
Posted by Michael Wonder on 16 Jan 2023
SMC - January 2023 decisions
16 January 2023 - The Scottish Medicines Consortium, which advises on newly-licensed medicines for use by NHSScotland, has today published ...
Posted by Michael Wonder on 28 Nov 2022
Joint statement: NICE and SMC/HIS collaboration
25 November 2022 - NICE and SMC/HIS collaboration on the health technology appraisal of tixagevimab–cilgavimab (Evusheld) for preventing COVID-19. ...
Posted by Michael Wonder on 11 Oct 2022
Scotland backs three new uses for MSD’s Keytruda
11 October 2022 - Scotland has become the first country in the UK to back NHS funding for the use ...
Posted by Michael Wonder on 10 Oct 2022
SMC - October 2022 decisions
10 October 2022 - The SMC has today published advice on new medicines for six different conditions. ...
Posted by Michael Wonder on 14 Sep 2022
Jazz Pharmaceuticals receives SMC approval for reimbursement of Sativex
14 September 2022 - Therapy is for the treatment of spasticity due to multiple sclerosis. ...